
Pardes Biosciences Investor Relations Material
Latest events

Q1 2023
5 May, 2023

Q4 2022
14 Mar, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pardes Biosciences Inc
Access all reports
Pardes Biosciences Inc. is a biopharmaceutical company that was focused on the discovery, development, and commercialization of novel oral antiviral therapeutics. The company targeted life-threatening diseases, including its efforts against COVID-19. Pardes Biosciences operated as a clinical-stage company, which indicates its products were in the clinical trial phase and not yet available on the market. As of August 31, 2023, Pardes Biosciences was acquired by MediPacific, Inc., and it became a wholly owned subsidiary of MediPacific. Following the acquisition, the shares of Pardes Biosciences ceased trading and were delisted from the Nasdaq stock exchange.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
PRDS
Country
🇺🇸 United States